CAJ | 학술논문

目的：探讨度洛西汀联合小剂量奥氮平治疗躯体形式障碍患者的疗效和安全性。方法：120例躯体形式障碍患者随机分为研究组即度洛西汀联合小剂量奥氮平组和对照组即单用度洛西汀组，各60例疗程6周。治疗前后以汉密尔顿焦虑量表（HAMA）、密尔顿抑郁量表（HAMD）的疑病条目、阿森斯失眠量表（AIS），临床疗效总评量表（CGI）进行疗效评估，以治疗时出现的症状量表（TESS）评估用药的安全性。结果：治疗第2周，研究组 HAMA 和 CGI-GI 评分显著低于对照组（P 均<0.01）。治疗第6周，两组显效率基本接近，对照组的疑病观念的残留率高于研究组（P <0.05）。两组第2、4、6周的 HAMA 评分均显著低于治疗前（P <0.01）。第1周及第6周，对照组的治疗脱落率显著高于研究组（P 均<0.05）。治疗第1周末，对照组的恶心呕吐以及失眠的发生率显著高于研究组（ P <0.05）。
목적：탐토도락서정연합소제량오담평치료구체형식장애환자적료효화안전성。방법：120례구체형식장애환자수궤분위연구조즉도락서정연합소제량오담평조화대조조즉단용도락서정조，각60례료정6주。치료전후이한밀이돈초필량표（HAMA）、밀이돈억욱량표（HAMD）적의병조목、아삼사실면량표（AIS），림상료효총평량표（CGI）진행료효평고，이치료시출현적증상량표（TESS）평고용약적안전성。결과：치료제2주，연구조 HAMA 화 CGI-GI 평분현저저우대조조（P 균<0.01）。치료제6주，량조현효솔기본접근，대조조적의병관념적잔류솔고우연구조（P <0.05）。량조제2、4、6주적 HAMA 평분균현저저우치료전（P <0.01）。제1주급제6주，대조조적치료탈락솔현저고우연구조（P 균<0.05）。치료제1주말，대조조적악심구토이급실면적발생솔현저고우연구조（ P <0.05）。
Objective:To explore the efficacy and safety of duloxetine combined with low dose olanzapine in the treatment of somatoform disorders. Method:A total of 120 patients with somatoform disorders were randomly divided into study group with duloxetine combined with small dosage of olanzapine and control group with duloxetine for the treatment of somatoform disorders for 6 weeks. They were assessed using Hamilton anxiety scale(HAMA),Hamilton depression scale(HAMD),Athens insomnia scale(AIS),clinical global impression (CGI)to evaluate the efficacy and treatment emergent side effect scale( TESS)to evaluate the safety. Results:In the 2nd weekend,the scores of HAMA and CGI-GI in study group were significantly lower than those in control group(all P < 0. 01). In the 1st and 6th weekend,the dropout rate of control group was significantly larger than that of study group(all P < 0. 05). In the 1st weekend,the incidence rate of nausea and vomiting in control group was significantly larger than that in study group. Conclusion:Duloxetine combined with small dosage of olanzapine in the treatment of somatoform disorder takes effects faster than single duloxetine and has lower dropout rate.